Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oxybuprocaine→

Oxybuprocaine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
99-43-4
Molecular formula
C17H28N2O3
Molecular weight
308.4 g/mol
Drug class
Ester-type local anaesthetictopical ophthalmic anaesthetic
Mechanism of action
Reversibly blocks voltage-gated sodium channels in neuronal membranes, preventing initiation and conduction of nerve impulses and producing local surface anaesthesia.
Indications / reported uses
  • Topical anaesthesia of the eye for short ophthalmic procedures, including tonometry, gonioscopy and removal of superficial foreign bodies, according to the product label.

Sources: https://www.medicines.org.uk/emc/product/102348/smpc · https://www.medicines.org.uk/emc/product/3739/smpc · https://www.safetyandquality.gov.au/medicine-finder/minims-oxybuprocaine-eye-drops · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oxybuprocaine Environmental Risk Assessment (ERA) (the Oxybuprocaine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.